Periodontal and Biochemical Correlations during Alendronate Treatment in Postmenopausal Women: A Longitudinal Study

Authors

  • Aseel Jalil Ibrahim Al-Karawi Faculty of Dental Medicine
  • Hajer Ali Ahmed Hentati

DOI:

https://doi.org/10.5195/d3000.2025.813

Keywords:

Postmenopausal, Osteoporosis, Alendronate, Periodontal clinical parameters, Calcium, Bone remodeling markers, Osteoprotegrin

Abstract

Objective: Postmenopausal osteoporosis (OP) is a prevalent condition often treated with bisphosphonates like alendronate, which may influence periodontal health. In this study, we aimed to evaluate the relationship between clinical periodontal parameters [probing pocket depth (PPD), clinical attachment level (CAL)], biochemical markers [osteoprotegerin (OPG), and calcium (Ca)] and alendronate therapy.

Methods: This case-control study was carried out on 60 females aged from 55 to 65. All participants were divided into two groups equally, group A that included healthy postmenopausal females with healthy periodontium and group B included patients with osteoporosis. Patients were followed up for one year through for three consecutive periods (0, 6, and 12 months) after receiving alendronate (ALN) treatment. Patients with osteoporosis or ALN were further subdivided equally based on gingivitis and periodontitis. Blood samples were gathered for quantitative proportions of OPG through enzyme–linked immune sorbent assay (ELISA). Additionally, calcium was analyzed using full automated calcium detector device. The clinical periodontal parameters (PPD, and CAL) were reported for all teeth except for third molars and kept in specifically designed case sheet documents following assortment of serum.

Results: There was a significant decrease in PPD and CAL after 12 months of ALN treatment. However, there was significant increase in serum OPG and calcium level at each consecutive recall follow up in comparison to no ALN treatment. Additionally, our study revealed a positive correlation between OPG and calcium at base line in patients with osteoporosis (p<0.001).

Conclusion: Probing pocket depth, clinical attachment level and osteoprotegerin and calcium serum levels improved significantly with alendronate therapy.

Downloads

Published

2025-02-12

Issue

Vol. 13 No. 1 (2025)

Section

Adults & the Elderly

License

Copyright (c) 2025 Aseel Jalil Ibrahim Al-Karawi, Hajer Ali Ahmed Hentati

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site;
    with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
  4. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
  5. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
  6. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
  7. The Author represents and warrants that:
    1. the Work is the Author’s original work;
    2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
    3. the Work is not pending review or under consideration by another publisher;
    4. the Work has not previously been published;
    5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
    6. the Work contains no libel, invasion of privacy, or other unlawful matter.
  8. The Author agrees to indemnify and hold Publisher harmless from Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Revised 7/16/2018. Revision Description: Removed outdated link.